These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8234467

  • 1. Photobleaching of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
    Spikes JD, Bommer JC.
    Photochem Photobiol; 1993 Sep; 58(3):346-50. PubMed ID: 8234467
    [Abstract] [Full Text] [Related]

  • 2. Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
    Spikes JD, Bommer JC.
    J Photochem Photobiol B; 1993 Feb; 17(2):135-43. PubMed ID: 8459317
    [Abstract] [Full Text] [Related]

  • 3. Quantum yields and kinetics of the photobleaching of hematoporphyrin, Photofrin II, tetra(4-sulfonatophenyl)-porphine and uroporphyrin.
    Spikes JD.
    Photochem Photobiol; 1992 Jun; 55(6):797-808. PubMed ID: 1409888
    [Abstract] [Full Text] [Related]

  • 4. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
    Taber SW, Fingar VH, Coots CT, Wieman TJ.
    Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
    [Abstract] [Full Text] [Related]

  • 5. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
    Wong Kee Song LM, Wang KK, Zinsmeister AR.
    Cancer; 1998 Jan 15; 82(2):421-7. PubMed ID: 9445202
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
    Mori K, Ohta M, Sano A, Yoneya S, Sonoda M, Kaneda A, Sato Y.
    Nippon Ganka Gakkai Zasshi; 1997 Feb 15; 101(2):134-40. PubMed ID: 9124093
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
    Nakagawa H, Matsumiya T, Sakaki H, Imaizumi T, Kubota K, Kusumi A, Kobayashi W, Kimura H.
    Oral Oncol; 2007 Jul 15; 43(6):544-50. PubMed ID: 17257889
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
    Chan AL, Juarez M, Allen R, Volz W, Albertson T.
    Photodermatol Photoimmunol Photomed; 2005 Apr 15; 21(2):72-8. PubMed ID: 15752124
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
    Kobayashi W, Liu Q, Nakagawa H, Sakaki H, Teh B, Matsumiya T, Yoshida H, Imaizumi T, Satoh K, Kimura H.
    Oral Oncol; 2006 Jan 15; 42(1):46-50. PubMed ID: 16266818
    [Abstract] [Full Text] [Related]

  • 14. Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP.
    Tsai SR, Yin R, Huang YY, Sheu BC, Lee SC, Hamblin MR.
    Photodiagnosis Photodyn Ther; 2015 Mar 15; 12(1):123-30. PubMed ID: 25462575
    [Abstract] [Full Text] [Related]

  • 15. Amino Acid Derivatives of Chlorin-e6-A Review.
    Vicente MDGH, Smith KM.
    Molecules; 2023 Apr 14; 28(8):. PubMed ID: 37110713
    [Abstract] [Full Text] [Related]

  • 16. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
    Wong TW, Aizawa K, Sheyhedin I, Wushur C, Kato H.
    J Pharmacol Sci; 2003 Oct 14; 93(2):136-42. PubMed ID: 14578580
    [Abstract] [Full Text] [Related]

  • 17. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
    Webber J, Leeson B, Fromm D, Kessel D.
    J Photochem Photobiol B; 2005 Feb 01; 78(2):135-40. PubMed ID: 15664500
    [Abstract] [Full Text] [Related]

  • 18. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
    Ferrario A, Kessel D, Gomer CJ.
    Cancer Res; 1992 May 15; 52(10):2890-3. PubMed ID: 1581904
    [Abstract] [Full Text] [Related]

  • 19. Mono-(L)-aspartylchlorin-e6.
    Hargus JA, Fronczek FR, Vicente MG, Smith KM.
    Photochem Photobiol; 2007 May 15; 83(5):1006-15. PubMed ID: 17880493
    [Abstract] [Full Text] [Related]

  • 20. Talaporfin: LS 11, LS11, ME 2906, mono-L-aspartyl chlorin e6, NP e6, NPE 6, taporfin sodium.
    Drugs R D; 2003 May 15; 4(1):69-71. PubMed ID: 12568643
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.